Loading
Co-discovered that PARP inhibitors kill BRCA-deficient cells, the synthetic lethality behind olaparib and its successors.
Thomas Helleday's laboratory published, back-to-back with Alan Ashworth's, the 2005 Nature paper showing that BRCA2-deficient cells are exquisitely sensitive to PARP inhibition, the discovery that led to olaparib, niraparib, rucaparib and talazoparib and established synthetic lethality as a drug-discovery strategy. He later developed the MTH1 inhibitor concept and continues to work on DNA repair targets.
| Title | Journal | Year |
|---|---|---|
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Nature | 2005 |
| The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings | Molecular Oncology | 2011 |
Shares Synthetic lethality approaches, PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares Synthetic lethality approaches, PARP, PARP inhibitors, Olaparib.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares Synthetic lethality approaches, PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD).
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.